Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Recruiting 3Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 18OTHER 5NETWORK 2NIH 1

Study Type

Interventional 5Expanded_access 1

Sponsor

Cancer Type

Plasma cell 2Tumor-Agnostic 1Sarcoma 1Breast 1

Conditions

Neoplasms 2Multiple Myeloma 2Paraproteinemias 1Neoplasms, Plasma Cell 1Hematologic Diseases 1Desmoid Tumors 1Corneal Diseases 1Breast Neoplasms 1Blood Protein Disorders 1

Interventions

Cyclophosphamide 2040Radiotherapy 1854Cisplatin 1820Carboplatin 1530Gemcitabine 1432Paclitaxel 1289Bevacizumab 1267Docetaxel 1200pembrolizumab 1196Oxaliplatin 1157Capecitabine 1140Fluorouracil 1059Dexamethasone 971Rituximab 918Nivolumab 908Magnetic Resonance Spectroscopy 858Etoposide 839Doxorubicin 823Drug Therapy 789Radiosurgery 774Irinotecan 774Cytarabine 736fludarabine 714Leucovorin 674Lenalidomide 608fludarabine phosphate 564Temozolomide 552Filgrastim 540Radiation 539Cetuximab 535

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Interventional × nirogacestat × Clear all
NCT05879146 2026-05-15

Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Tumor-Agnostic

Neoplasms

NCT05556798 2026-02-24

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
9 enrolled
Plasma cell

Multiple Myeloma

NCT05949099 2025-09-08

Study of Cryoablation and Nirogacestat for Desmoid Tumor

Stanford University

Phase 2 Recruiting
28 enrolled
Sarcoma

Desmoid Tumors

NCT05573802 2023-10-24

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Hellenic Society of Hematology

Phase 1/2 Recruiting
36 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT02338531 2016-04-29

RHEA

Jules Bordet Institute

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡